NWM
NKTR icon

Nova Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

Nova Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40
Closed -$1.69K – 607
2025
Q4 		$1.69K Buy
40
+24
+150% +$1.34K ﹤0.01% 522
2025
Q3 		$910 Buy
16
+6
+60% +$199 ﹤0.01% 554
2025
Q2 		$258 Buy
+10
New +$112 ﹤0.01% 729

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nova Wealth Management's NKTR Position: Q1 2026 in Review

Nova Wealth Management sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 40 shares — an estimated $1.69K sold.

Nova Wealth Management first reported a position in NKTR in Q2 2025 and held it in 3 quarters. The position peaked at $1.69K in Q4 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Nova Wealth Management reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Nova Wealth Management sold 40 Nektar Therapeutics shares in Q1 2026, an estimated $1.69K.
  • Nova Wealth Management first reported a position in Nektar Therapeutics in Q2 2025 and held it in 3 quarters.
  • Nova Wealth Management's Nektar Therapeutics position peaked at $1.69K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Nova Wealth Management's 13F filing for Q1 2026, filed 14 Apr 2026.